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AbstRAct
Optimising the dosing of medicines for neonates 
and children remains a challenge. The importance of 
pharmacokinetic (PK) and pharmacodynamic (PD) 
research is recognised both in medicines regulation 
and paediatric clinical pharmacology, yet there remain 
barriers to undertaking high-quality PK and PD studies. 
While these studies are essential in understanding 
the dose–concentration–effect relationship and 
should underpin dosing recommendations, this review 
examines how challenges affecting the design and 
conduct of paediatric pharmacological studies can be 
overcome using targeted pharmacometric strategies. 
Model-based approaches confer benefits at all stages 
of the drug life-cycle, from identifying the first dose 
to be used in children, to clinical trial design, and 
optimising the dosing regimens of older, off-patent 
medications. To benefit patients, strategies to ensure 
that new PK, PD and trial data are incorporated into 
evidence-based dosing recommendations are needed. 
This review summarises practical strategies to address 
current challenges, particularly the use of model-based 
(pharmacometric) approaches in study design and 
analysis. Recommendations for practice and directions 
for future paediatric pharmacological research are given, 
based on current literature and our joint international 
experience. Success of PK research in children requires 
a robust infrastructure, with sustainable funding 
mechanisms at its core, supported by political and 
regulatory initiatives, and international collaborations. 
There is a unique opportunity to advance paediatric 
medicines research at an unprecedented pace, bringing 
the age of evidence-based paediatric pharmacotherapy 
into sight.
IntRoDuctIon
The importance of improving pharmacotherapy 
for children is widely recognised. Until recently, 
only 30% of medications used in paediatrics in the 
USA were actually studied in children.1 The lack of 
appropriate drug labelling for children is a long-
standing problem,2 which also has implications for 
drug safety, particularly in neonates.3 High-quality 
pharmacokinetic (PK) and pharmacodynamic (PD) 
studies are an essential component of understanding 
the dose–concentration–effect relationship and 
should underpin dosing recommendations in chil-
dren. Without PK data from appropriate popula-
tions to support marketing authorisations, clinicians 
have little choice but to use medications off-label, 
which can lead to increased risk of toxicity or 
subtherapeutic dosing. During drug development, 
model-based (pharmacometric) approaches can be 
used in several ways, including identifying the dose 
regimen for different age groups in order to inform 
clinical trial design. PK/PD models can inform the 
expected effect size during sample size calculations, 
reducing the burden of unnecessary research, and 
also help refine dosing strategies relevant to routine 
clinical practice.
Despite detailed guidance on adult PK/PD 
research, specific challenges affect the design and 
conduct of paediatric pharmacological studies. This 
review defines the key challenges encountered, 
exploring solutions and providing recommenda-
tions for practice and future research.
Paediatric PK studies: what are they?
PK studies absorption, distribution, metabolism and 
excretion of drugs. PK studies guide the determi-
nation of a drug’s optimal route of administration 
and formulation, and appropriate dose and dose 
schedule(s). PK studies include (1) early-phase 
studies including PK components, comprising (a) 
first-dose-in-child studies and (b) phase II and III 
studies; and (2) phase IV postmarketing PK studies 
(including, eg, dose optimisation or therapeutic 
drug monitoring (TDM) studies).
Paediatric research is challenging because chil-
dren are considered vulnerable and sample sizes are 
small. Nevertheless, accurate dosing is paramount 
to safe and effective treatment, which makes paedi-
atric PK studies essential. The USA and European 
Union (EU) have adopted paediatric clinical trial 
regulations to address historic deficiencies in this 
research.4 These reflect the recent paradigm shift 
in attitudes recognising that ‘the time has come to 
protect children and young people through research 
not from research’.5
Knowledge gaps in developmental physiology 
and pharmacology
Physiological development, including physical 
growth and the maturation of organs, transporters 
and enzymes, creates size and age-dependent vari-
ability in PK parameters. PK measures should there-
fore be related to measures of growth, including age, 
weight or body surface area (BSA).6 The heteroge-
neity in paediatric patient populations contributes 
to large PK variability: neonates, for example, can 
have a tenfold weight range (eg, 400 g–4 kg) in addi-
tion to differing gestational ages and postmenstrual 
ages. Critical illness, renal replacement therapy and 
cardiopulmonary bypass can also influence PK, 
as well as drug–drug interactions.7 Furthermore, 
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genetic differences (polymorphisms) contribute to variability in 
drug disposition and response. A deeper understanding of the 
interplay between genetic polymorphisms, growth and devel-
opment is urgently needed to be able to provide personalised 
dosing to children of different ages, underlying disease states and 
treatments.8
challenges in paediatric PK
Traditional PK study designs involve a single dose with multiple 
blood samples at fixed intervals, covering a time period of up 
to approximately 10 half-lives. Multiple samples per patient, 
with varying routes of administration, enable calculation of 
individual drug exposure (area under the plasma drug concen-
tration–time curve: AUC), and the rate and extent of absorp-
tion. Such studies generally require the same number of samples 
from all subjects taken at the same time in the dosing interval. 
These designs present ethical and practical barriers for children. 
Similar challenges arise later in the drug life-cycle when needing 
to undertake verification of bioequivalence or cross-over relative 
bioavailability studies in children in order to exclude age-by-for-
mulation interactions.
First, the number of samples and the blood volume per sample 
that can safely be taken in children—especially neonates—are 
limited.9 Second, it is impractical to collect many samples over a 
long period, without interfering with patient care and length of 
stay. Phlebotomy-related barriers partly concern the acceptability 
of additional sampling in children, particularly when venepunc-
ture is not needed for clinical care. Similar challenges arise later 
in the drug life-cycle when needing to undertake verification of 
bioequivalence or cross-over relative bioavailability studies in 
children in order to exclude age-by-formulation interactions. 
In neonatal studies, differences in postmenstrual age, body 
composition and end-organ perfusion create extensive PK vari-
ability, reflecting rapid phases of growth and maturation. Usually, 
prior to neonatal PK studies, evidence should be established in 
less vulnerable populations.3 However, particularly in condi-
tions unique to newborns, neonatal PK data should be obtained 
a priori.3 Current regulations stipulate that the volume of blood 
samples for research should not exceed 1% at any one time 
(0.8 mL/kg) or 3% within 1 month, that is, 1.2 mL for a neonate 
weighing 500 g, which is problematic for many assays.3 10
sampling techniques for blood and other biological matrices
Advances in analytical technology have dramatically reduced the 
blood volume required, yet novel biological sampling methods 
have been relatively underused. Microsampling techniques (eg, 
dried blood spots) are now possible with ultrasensitive analytical 
methods (eg, liquid-chromatography with tandem mass-spec-
trometry), potentially reducing sample volumes to 5–10 μL, 
sometimes also reducing invasiveness and improving analyte 
stability.10
A thorough understanding of different paediatric blood 
sampling techniques, summarised in table 1, is paramount for 
PK study design. Research methods which reduce the burden 
of blood sampling, including so-called ‘scavenged’ sampling11 
(using left-over blood from clinical samples) or opportunistic 
sampling (sampling at the same time as clinical blood tests), 
can be used but also require careful validation, to ensure they 
provide equivalent estimation of PK parameters when compared 
to preplanned sampling time points.12
The collection of alternative matrices to blood requires 
special consideration in children. Whenever possible, PK/
PD information should be obtained via less invasive matrices 
such as urine and saliva. If an indwelling bladder catheter 
is present and a reliable quantitative assay available, urine 
samples can also be obtained to minimise necessary blood 
sampling.3 Limitations of these approaches include analyt-
ical complexity, potential impact of collection methods and 
environmental factors (eg, temperature and pH) on analyte 
recovery, and practical challenges. Urinary sampling methods 
are summarised in table 2. The urine output must be collected 
over a prolonged (prespecified) period to measure cumulative 
drug (or metabolite) excretion per unit time, but collection 
periods are often logistically challenging in practice, deviating 
from clinical routines.
Saliva has shown feasibility for caffeine TDM in preterm 
infants13 but requires characterisation of the relationship 
between saliva and plasma concentrations. Several factors can 
drive variability in salivary measurements, including salivary pH 
and drug physicochemical properties (molecular weight, pKa). 
Importantly, salivary sampling in neonates can also be time-con-
suming, for example requiring prolonged oral cavity suctioning 
(up to 30 min), thereby potentially posing additional ethical 
concerns. Often samples from tissues of interest are more infor-
mative in understanding PK/PD, so suitable opportunities to 
use left-over clinical samples (eg, cerebrospinal fluid) should be 
taken. However, the cost of developing and validating bioanalyt-
ical assays in different sampling matrices must be incorporated 
into study feasibility assessments. All assays should be devel-
oped in accordance with relevant guidelines to meet regulatory 
requirements.14
Ethical issues in paediatric PK studies
The ethical principles of paediatric research are well described 
elsewhere.15 PK research presents specific challenges surrounding 
the informed consent process and the risk–benefit of study partic-
ipation. Potential research participants (and/or their parents) 
need sufficient information and time to make an informed deci-
sion. PK samples, however, may be required soon after drug 
administration. If this follows an emergency procedure, parents 
may be absent or under too much stress to consent. In these 
circumstances, deferred consent may be appropriate subject to 
ethics committee approval. For newborns, prenatal consent can 
be suitable.
To be ethically acceptable, participation of children should 
be limited to research of minimal risk and burden, or with 
the potential for direct benefit.16 Risk assessments can be 
difficult in paediatric studies with minimal adult safety data, 
for example if drug toxicity prevents healthy adult studies. 
Furthermore, dose-finding PK studies may not provide direct 
participant benefit, posing the dilemma of balancing individual 
research-associated burdens with intended long-term benefits 
to future children.
PK modelling as a solution
To circumvent some of the challenges described above, a 
model-based approach to PK study design and analysis can be 
employed. In population PK (popPK) modelling, data from 
multiple subjects are analysed simultaneously, thus allowing 
patients to contribute data with varying sample numbers and 
timing. Modelling is used to estimate typical values of PK 
parameters for the population. Capturing information from 
a larger number of patients enables improved understanding 
of PK variability and thus improved generalisability of study 
results.17 However, PK parameters for individuals can also be 
estimated within the same process, making this method highly 
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efficient. PopPK modelling using non-linear mixed effects 
(NLME) is now the standard method of choice. PK data (drug 
concentration–time profiles) are generally non-linear; hence, 
PK model fitting requires non-linear regression. The mixed-ef-
fects approach gives less biased and more precise estimates of 
variability than other methods.18 NLME is implemented in 
many general and specialist statistical tools and enables quan-
tification of interindividual variability, intraindividual vari-
ability and residual unexplained variability. During PK model 
building, significant factors determining PK variability are 
identified (covariates, eg, age, weight, renal function). Within 
a mixed-effects popPK model, there are ‘fixed effects’—
including the typical PK parameters, described by the PK struc-
tural model, and significant covariates—and ‘random effects’, 
which quantify variability at the parameter and observation 
levels.17 PK modelling confers many benefits (see box 1) and 
has many applications, including (1) model-based dose optimi-
sation, (2) extrapolation for paediatric dose regimen selection, 
table 1 Paediatric blood sampling procedures that may be employed in pharmacokinetic studies or clinical trials
Method of blood 
sampling Advantages Disadvantages Preferred age group(s) comments
Sampling from an 
indwelling arterial 
catheter or central 
venous line
No need for separate invasive 
procedures (that would require 
additional needles).
If such a line is already in place 
for clinical purposes, the risks 
associated with blood sampling 
are limited.
Potential infection risk from 
additional accessing of the line; 
blood loss due to inappropriate 
line handling; premature loss of 
the line. Sometimes additional 
blood volume (dead-space) 
needed to clear the line of other 
infusion fluids.
Method feasible in all 
age groups.
Some centres return this dead-space volume 
directly after sampling, while others consider it 
unhygienic, dependent on the structure of the 
specific line system used and local practice.
Method commonly used in intensive care 
settings.
Cannulation-based 
venepuncture
Different options are possible, 
either multiple or single use 
of an intravenous cannula. 
With multiple use of a single 
intravenous cannula, the burden 
of the insertion is reduced to 
only once.
Often multiple attempts are 
needed before successful 
peripheral cannulation. The 
blood flow may be too slow and 
blood may clot in the cannula 
system, even when intermittent 
or continuous saline flushes are 
instilled in the cannula.
For smaller children, open 
collection systems are more 
appropriate.
In very small children, repeated sampling from 
one cannula may also be difficult.
Venepuncture (without 
cannulation)—(1) 
vacuum systems
Several methods can be used: in 
older children, simple vacuum 
systems in large veins are most 
frequently employed. Discomfort 
can be reduced by appropriate 
use of local anaesthetic cream.
Usually involves study-specific 
invasive procedure. Less suitable 
for younger children. Not suitable 
for some children who have 
experienced very high numbers 
of routine blood tests (eg, in 
oncology).
Preferred in older children. 
In younger infants and 
neonates, these methods are less 
practical or even unfeasible, as 
the size of the vein means the 
vacuum will collapse the vessel 
so no blood can be taken.
Culturally specific factors can be important: 
parents in some countries are happy for their 
children to have extra blood tests at any age, 
whereas other cultures can be very against the 
invasiveness of the method.
Venepuncture—(2) 
non-vacuum methods: 
for example, the use 
of syringe needles 
or the needle from a 
Vacutainer system
These needles are easier to 
insert and manipulate in small 
veins than intravenous cannulae 
and have less problems with 
blood clotting, due to the large 
bore size (syringe needles) and 
heparin coating (Vacutainer 
needles).
This method needs practice by 
specifically trained personnel.
Preferable for younger children 
(in whom vacuum-based systems 
and/or cannulation may be 
difficult).
In all these non-vacuum methods, blood needs 
to drop in opened tubes. In general blood 
samples up to 5 mL per occasion can be taken, 
before the blood starts to clot, but it is widely 
variable per patient and becomes less with 
decreasing age.
Capillary sampling: 
heel prick or finger 
prick
The advantage of finger/
heel pricks is that they can be 
easily taught to parents and 
children.
This method can be less invasive 
and painful than venepuncture 
or intravenous cannulation 
(although this is debatable).
Capillary sampling is not always 
comfortable: studies have shown 
that venepuncture is preferred 
over finger pricks in older 
children. Also, to obtain adequate 
blood volumes, repeated 
punctures may be needed, 
and also continued pressing 
of the foot or fingers, which is 
uncomfortable.
The heel prick method is often 
preferred in neonates when 
normal venepuncture and 
cannulation are not required for 
clinical reasons.
Since this can be taught to children or their 
carers, they may be able to collect blood samples 
at home, in connection with dried blood spot 
analysis.
table 2 Urinary sampling methods in pharmacokinetic (PK) studies
Methods Pros and cons
Midstream urine sample Feasible for older children who can follow instructions. Not suitable for young children.
Urinary catheter sampling This method is generally limited to children with indwelling urinary catheters (IDC) for clinical care, since IDC insertion purely for research is 
unacceptable in most jurisdictions.
Urinary adhesive bags These bags may seem more practical (than awkward time collection periods), but this method is notoriously unreliable. The adhesive often comes 
loose and urine leaks in the diaper. Repeated urine bag adhesion may damage the vulnerable skin in young infants.
Gauze-diaper methods Urine can be collected in cotton balls or gauzes separated from the diaper interior by a plastic film. By weighing the diaper at each time interval, 
the total urine volume can be deduced and urine for PK analyses can be expressed from the cotton. Care must be taken to ensure that the drug is 
fully recovered from the urine. Also, frequent diaper changes may not be allowed in very young infants, where minimal handling and procedures 
are standard of care.
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(3) clinical trial simulations, (4) model-based TDM algorithms 
and (5) enhancing understanding of developmental pharma-
cology.17 19
scaling and extrapolation
Scaling refers to normalising data either between species or 
between humans of different ages and sizes. PK models usually 
aim to estimate drug exposure (AUC), which under steady-state 
conditions depends only on dose and clearance (CL). In 1950, 
Crawford, a paediatrician, recognised CL scales approximately 
with BSA, and described the apparent parallel between CL 
scaling and that of basal metabolic rate with the so-called allo-
metric model.20 Allometric scaling of CL a priori is now common 
in PK modelling and is an appropriate way to scale for size in 
children over 2 years of age; box 2 gives the standard allometric 
model.21
Delineation of the correlated effects of weight, age and organ 
function is challenging, generating debate regarding the appro-
priate value of the allometric exponent (b). Knowledge from 
interspecies and biological process scaling, and anthropomor-
phic measurements (eg, organ sizes22), has identified 0.75 as 
a reasonable value for b when scaling CL, and 1 when scaling 
the volume of distribution.21 Weight raised to the power of 0.75 
describes clearance well in children over 2 years old but may not 
address preceding age-related maturational effects.23 This can 
be overcome using a standard parameterisation, incorporating 
allometric weight scaling and a sigmoid maturation function.6 
Germovsek et al23 compared this model with distinct clearance 
covariate models systematically identified in the literature to fit 
the same data set. No published model gave a superior fit to the 
standard model, providing a powerful argument for researchers 
to adopt a standard parameterisation, facilitating comparison of 
studies of the same drug and model-based meta-analysis.
Renal function (as related to clearance) is a common covariate 
in PK studies. The Food and Drug Administration (FDA) draft 
guidance24 recommends use of the Schwartz formula in children 
under 12 years and the Cockroft-Gault equation in adolescents. 
This recommendation leads to two fundamental problems: first, 
the methods use demographics (eg, height, weight, age) to esti-
mate glomerular filtration rate (GFR), which may already have 
entered the model (eg, via allometric scaling with a maturation 
function); and second, the methods have different units: mL/
min/1.73 m2 for Schwartz and mL/min for Cockroft-Gault, 
respectively. One sensible solution would be to avoid GFR, and 
instead use serum creatinine alongside allometric scaling and a 
maturation function. Since serum creatinine levels change with 
age (high at birth, falling rapidly, then rising again), this must be 
scaled by the age-expected median serum creatinine; an elegant 
method is available.25 However, the contribution of muscle mass 
and maternal creatinine transfer in preterm neonates must be 
considered.26
Extrapolation is defined as ‘Extending information and 
conclusions available from studies in one or more subgroups of 
the patient population (source population) to make inferences 
for another subgroup of the population (target population)’.27 
For drugs with an established linear PK profile in adults and 
where sufficient knowledge is available regarding disease aeti-
ology in children, often a single-dose study generates sufficient 
evidence for a paediatric PK assessment.24 The FDA provides an 
algorithm (‘decision tree’) to guide appropriate extrapolation for 
paediatric medicines.28 Evidence of similar disease progression, 
concentration–response relationships and comparable endpoints 
allows the extrapolation of PK and safety studies to support 
paediatric dosing rationale.28 29 New adverse effects may subse-
quently be identified in children relating to developmental PD, 
mandating ongoing safety monitoring throughout each agent’s 
life-cycle.
Dose selection for first-in-child studies: innovative methods
Often there is limited safety information to support dose selec-
tion in an initial paediatric PK study. The initial dose requires 
attention to (1) relative bioavailability, (2) age group and weight 
of study participants, (3) therapeutic index and (4) PK data from 
other populations and preclinical studies.24 Advantages of various 
dose-finding study designs (parallel, staggered, intrapatient dose 
titration) are summarised elsewhere.29 Current guidelines stipu-
late that the initial dose should be given as a fraction of the dose 
calculated from adult exposure based on the aforementioned 
factors and any additional paediatric expertise.24 However, the 
box 1 Key advantages of population model-based 
approaches to paediatric PK studies
 ► Study samples do not need to be taken at exactly the same 
time in all patients.
 ► The burden of study samples can be distributed among many 
patients.
 ► Capturing data from a larger number of patients enables 
improved understanding of PK variability.
 ► Data for popPK studies can be collected in patients who 
are already receiving the drug of interest as part of normal 
clinical care.
 ► Optimal sampling times can be identified to improve 
estimation of key PK model parameters.
 ► Flexible study designs with sparse sampling strategies 
facilitate better coordination with clinical care.
 ► Model-based sample size calculations may incorporate prior 
PK data.
 ► Model-based analyses can evaluate additional complex 
factors including drug–drug interaction models, disease 
progression, the placebo effect and data censoring.
 ► Improved mechanistic understanding of drug effect (theory 
enrichment).
 ► Facilitation of extrapolation beyond observed data.
 ► Data synthesis: capture and integration of data from different 
studies.
 ► Hypothesis generation (during the learning phase of drug 
development).
PK, pharmacokinetic; popPK, population PK. 
box 2 the standard allometric model
  yi = a · Wib  
yi is an individual’s biological parameter (eg, basal metabolic rate, 
drug clearance).
a is its value for a standard weight individual.
Wi is the individual in question’s weight.
b is the exponent by which the parameter changes with weight.
When b is 1 there is a linear relationship between the parameter 
and weight, when b<1 increasing weight leads to lower propor-
tional parameter increases, and when b>1 increasing weight 
leads to higher proportional parameter increases.
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role of modelling and simulation in dose selection is increasing, 
to help avoid children being exposed to subtherapeutic doses 
using current approaches. Extrapolation can involve ‘top-down’ 
scaling of adult PK (described above), or ‘bottom-up’ physiolo-
gy-based PK modelling, combining extensive information on the 
drug and the system (‘virtual child’)30 to estimate PK parameters. 
Ideally one should compare results from both approaches, with 
thorough investigation using sensitivity analysis to explain any 
differences.
To obviate potential toxicity and uncertainty surrounding 
first-in-child doses, some advocate microdosing (giving a very 
low dose), the feasibility of which has been demonstrated in 
infants.31 There are potential caveats, including limitations with 
assay performance and ethical concerns regarding subthera-
peutic dosing. An important prerequisite is dose linearity across 
the range from microdose to therapeutic dose: adult studies 
may be required first to establish this, or a thorough theoretical 
evaluation. Following the first dose, Bayesian (adaptive) study 
designs allow dose titration to quickly reach the desired thera-
peutic window, within either individual or sequential patients.
Realising an optimal design for PK studies
Optimal design refers to identification of the most informative 
study design, in order to optimise various aspects of the PK 
protocol, as summarised in box 3; results should be reviewed 
with consideration of practical and financial constraints.32
Many available software tools can help identify optimal 
study design.33 For paediatric PK studies, optimal design-based 
approaches could be viewed as an ethical requirement to minimise 
the number of children and the number of samples required.32 
One disadvantage is that optimal design relies heavily on the 
proposed model being useful for the target population. Since 
many PK studies are exploratory, it may not be possible to define 
an adequate model a priori. Therefore, study design should 
include techniques such as simulation re-estimation studies (to 
test whether a proposed design can recapture known parame-
ters) and ensure samples covering the whole dosing interval 
are included at the population level, if not in every patient. 
Solely opportunistic sampling can give poor model parameter 
estimates, and when feasible obtaining samples at rational time 
points should be coordinated with routine blood tests.34 When 
samples cannot be optimally timed, the so-called ‘scavenged’ 
sampling methods may be adopted, provided the analytes being 
studied are suitable.35
Recommendations for research in practice
We recommend incorporation of the steps summarised in table 3 
when designing paediatric and neonatal PK studies to maximise 
study quality and the feasibility of developing new evidence-
based dosing recommendations. Incomplete reporting of PK 
studies hinders the utility and comparability of study results, as 
highlighted by the 2015 consensus-based ClinPK statement.36 
The ClinPK minimum reporting criteria will most likely benefit 
from adaptation to address the unique challenges of paediatric/
neonatal PK study design, warranting future research.
changing clinical practice: implementing evidence-based 
formularies
Even when new PK studies are completed in children, these new 
data may be ignored by formulary committees and not used to 
inform future dosing recommendations. There are currently few 
transparent evidence-based paediatric and neonatal formularies, 
where the end users (ie, physicians or pharmacists) can easily 
access the evidence on which the dosing recommendations are 
based. The Dutch have reported their experience of developing 
and publishing an evidence-based formulary, with clear descrip-
tions of the timelines and funding required.37 This example 
demonstrates the feasibility of such endeavours and paves the 
way for other national and international formularies to follow 
suit. It is our belief that incorporating the latest PK evidence 
table 3 Steps to planning paediatric and neonatal pharmacokinetic studies
Protocol development The study team receives input from suitably trained expert(s), including paediatric/neonatal clinical pharmacologists, analytical chemists and 
pharmacometricians (with expertise in popPK modelling and statistics).
Study design The suitability and feasibility of optimal design is assessed.
Consider the potential influence of formulation on PK studies designed to optimise dose.
Sample size  ► The sample size calculation is informed by ‘optimal design’.
 ► The target age range(s) of study participants and the number of participants in each age group are determined.
 ► In preterm neonatal PK studies, investigators define how many subgroups of prematurity are included (usually banded by gestational age at birth 
and postnatal age).
Sampling plans  ► The number of samples needed per participant and their timing (optimum timing vs opportunistic, or a combination) is justified.
 ► Acceptable method(s) of sampling is defined.
Patient involvement Determine if there is a role for parent/child involvement in study design.
Analytical chemistry  ► Preferred matrix is confirmed (eg, blood vs serum or other biospecimen) and whether total or unbound concentrations will be measured.
 ► Stability of analytes in this matrix is verified (short-term and long-term, in relevant storage conditions).
Pharmacometrics Input from popPK statisticians is used for design questions above, and to plan which type of PK modelling is used and how to plan covariate analyses.
Implementation (1) Discuss with formulary committee where feasible to verify quantity and quality of new PK/PD data required to update paediatric or neonatal dosing 
recommendations.
Implementation (2) For larger, multicentre/international studies, liaison with the regulators can also be helpful to explore, for off-patent drugs, how much (new) paediatric/
neonatal PK data would be required to change the labelling.
PD, pharmacodynamic; PK, pharmacokinetic; popK, population PK. 
box 3 Features of study design that can be 
mathematically optimised
 ► Number of PK samples required per patient.
 ► Timing of PK samples within the dosing interval(s).
 ► Number of patients within a particular age group.
 ► Total sample size required for robust PK parameter estimates.
 ► Range of covariates to be included within each cohort (eg, 
range of renal (dys)function).
PK, pharmacokinetic. 
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bedside. Our vision for the life-cycle of paediatric therapeutics is 
summarised in figure 1.
current PK research needs
Funding and infrastructure for paediatric medicines research
While industry funds paediatric trials as requested by regula-
tors, large public funders, including the NIH (National Institutes 
of Health), the EU FP7 programme and the Medical Research 
Council, have all recently funded paediatric PK research initia-
tives, as have charities such as the Paediatric European Network 
for the Treatment of AIDS and Infectious Diseases.38 While such 
influential bodies continue to prioritise paediatric medicines, 
these streams are invaluable to support investigator-led research. 
PK research into widely used, old, off-patent medicines is essen-
tial to facilitate modern dose optimisation strategies and often 
depends on clinical academics seeking public funding; these 
endeavours are supported by, for example, the FDA and the 
European Medicines Agency priority lists, which retain focus on 
improving the evidence base for paediatric medicines, despite 
changing political agendas.
Given the new requirements for PK data in all age groups for 
new drugs, industry-partnered approaches should strengthen 
paediatric PK research, through sharing knowledge, exper-
tise and training opportunities. Funders should consider small 
pilot studies if required to design larger scale paediatric trials 
or where, for rare diseases when an adequately powered trial is 
unfeasible, research into using PK/PD surrogate endpoints as an 
alternative strategy is warranted. Separately, specific funding is 
needed for methodological aspects of PK/PD research including 
developmental pharmacology.
To date, trial conduct is often hampered by inadequate infra-
structure to support study delivery. Physicians may be uncon-
vinced of the need for paediatric PK studies, given perceived 
research burdens. Worldwide, most paediatric hospitals lack 
high-quality, Good Clinical Practice (GCP)-compliant infrastruc-
ture. Educating all paediatric healthcare professionals on the 
urgent need for such trials is of utmost importance.
For cost-effectiveness, specialist networks fostering and 
disseminating existing expertise are highly beneficial. Inter-
national initiatives such as the Global Research in Paediatrics 
(http://www. grip- network. org)39 and the new International 
Neonatal Consortium (https:// c- path. org/ programs/ inc/) are 
addressing the scarcity of expertise in paediatric clinical pharma-
cology. Sustainability will depend on adequate expertise and the 
training of future researchers. It is also important to recognise 
the major contributions of collaborative paediatric clinical trial 
networks, such as the National Institute for Health Research 
Clinical Research Network: Children, the Dutch Medicines for 
Children Research Network, Canada’s KidsCAN Trials and the 
Paediatric Trials Network.40 The recently launched  EU-funded 
Horizon PEDCRIN project aims to establish a European Paedi-
atric Clinical Trial Network, moving towards a continent-wide 
infrastructure. The continued funding of such dedicated 
networks will provide a solid infrastructure to underpin future 
activities.
Research agenda
An internationally embraced research agenda for paediatric PK 
is needed. All stakeholders including clinicians, researchers, 
policy makers, funders, patients and families should play a role 
in defining this. While no formal agenda exists, the current 
literature highlights knowledge gaps and areas requiring further 
development. The most urgent are the following:
 ► Increasing the number of paediatric studies collecting PK 
data.
 ► Evaluating the risk–benefit profile for conducting effi-
cacy studies without prior PK data, including ethical 
considerations.
Figure 1 Paediatric product life-cycle from development to implementation. PD, pharmacodynamic; PK, pharmacokinetic. 
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 ► Understanding renal function markers, and scaling renal 
function, identifying markers without the limitations of 
creatinine, for example, cystatin-C,26 and identifying new 
urinary biomarkers which, in addition to denoting drug-in-
duced kidney injury, may provide useful markers of impaired 
renal drug clearance.
 ► Promoting standardised minimum data recommenda-
tions and data sharing between researchers and formulary 
committees to facilitate evidence-based dosing recommen-
dations and timely updates across borders.
 ► Funding agencies should mandate a paediatric pharmacolo-
gist reviewer for all drug efficacy study protocols.
conclusIons
Although undertaking high-quality paediatric PK studies is chal-
lenging, the tools and expertise needed are now available and 
affordable. Model-based approaches address many obstacles in 
PK study design and delivery. Thus, there is a unique opportu-
nity to drive paediatric medicines research forward, providing 
adequate research infrastructure is developed and sustained. 
Political and practical support from regulators and physicians is 
paramount to the future success of these initiatives. As paediatric 
PK data continue to improve, we must create mechanisms for 
incorporating regular, rigorous reviews of the latest data into 
routine formulary updates, to ensure evidence-based dosing can 
be implemented to support rational paediatric pharmacotherapy. 
The importance of parallel paediatric PD research must not be 
forgotten, which we discuss in a related review.41 However, with 
the current energy and momentum in this field, it will be feasible 
to dramatically improve the evidence supporting optimal dosing 
of medicines for children in the near future, with great benefits 
for our patients.
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